Materiały źródłowe

• #1 Lambert-Eaton myasthenic syndrome | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/lambert-eaton-myasthenic-syndrome?embed_domain=Navimumbaihouses.com%2Fblog%2Fnews%2Fhow-youll-know-if-your-client-is-truly-motivated-to-buy%2F&lang=us

  LEMS is the second most common neuromuscular junction disease after myasthenia gravis. […] Up to two-thirds of LEMS present as a paraneoplastic syndrome secondary to malignancy, which is nearly always small-cell lung cancer.

• #1

  https://link.springer.com/article/10.1007/s00415-003-1063-7

  We studied the epidemiology of myasthenia gravis (MG) and the Lambert-Eaton myasthenic syndrome (LEMS), and their association with small cell lung carcinoma (SCLC) and thymoma, in a well defined region of the Netherlands. […] A total of 202 patients with MG (20 with thymoma) and ten patients with LEMS (seven with SCLC) were identified. […] LEMS was 46 times less prevalent (2.32 106) than MG (106.1 106), whereas the annual incidence rate of LEMS was 14 times lower (0.48 106) than of MG (6.48 106), reflecting the poor survival of LEMS patients with SCLC. […] This study confirms the increasing prevalence of MG over the last few decades as reported by others, and underscores the relative rarity of LEMS. […] The frequency of LEMS in our patients with SCLC was lower than reported in previous studies.

• #1 Lambert-Eaton myasthenic syndrome: Epidemiology and therapeutic response in the national veterans affairs population – PubMed

  https://pubmed.ncbi.nlm.nih.gov/27997683/

  One nationwide study (The Netherlands) of Lambert-Eaton myasthenic syndrome (LEMS) has been published. We report LEMS epidemiology and its therapeutic response in the United States Veterans Affairs (VA) population. […] Point prevalence was estimated at 2.6 per 1,000,000 (confirmed cases) and 3.3 per 1,000,000 (combined confirmed and probable cases). Crude prevalence was similarly estimated at 9.2 and 10.9 per 1,000,000 respectively. […] This investigation was a large North American epidemiologic study of LEMS. LEMS prevalence in the national VA population was found to be similar to previously published rates in other large international populations.

• #1 Lambert-Eaton Myasthenic syndrome: early diagnosis is key | DNND

  https://www.dovepress.com/lambert-eaton-myasthenic-syndrome-early-diagnosis-is-key-peer-reviewed-fulltext-article-DNND

  Lambert-Eaton myasthenic syndrome (LEMS) is an uncommon disorder of neuromuscular transmission with distinctive pathophysiological, clinical, electrophysiological and laboratory features. […] Underdiagnoses and frequent misdiagnoses interfere with accurate epidemiological estimations of LEMS. […] In the same study, the annual incidence was 0.4 per million with equal proportions of LEMS associated with SCLC and LEMS without SCLC. […] The estimated prevalence was 2.5 per million inhabitants, and there was a lower prevalence of P-LEMS that was probably due to poor survival in this group. […] The prevalence in the United States was indirectly estimated to be 1 in 100,000 based on the prevalence of small cell lung cancer. […] In a large and more recent North American epidemiologic study of LEMS, the annual incidence of confirmed cases was similarly estimated at 0.6 per million, and the prevalences were estimated at 2.8 and 3.8 per million for confirmed and probable cases, respectively.

• #1 Lambert-Eaton Myasthenic Syndrome – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK507891/

  LEMS is a rare neuromuscular disorder with a prevalence 46 times lower than myasthenia gravis (MG). However, the annual incidence of LEMS is only 10 to 14 times less than that of MG. This contrast in prevalence underscores the challenging prognosis and survival rates of LEMS, particularly when associated with SCLC. […] Approximately 60% to 75% of LEMS patients are male, whereas MG has a female predilection. The mean age at presentation for paraneoplastic LEMS in individuals is around age 58. On the other hand, in cases of LEMS not associated with an underlying malignancy, the age and gender distribution resemble that of MG. The onset age peaks at 35, with a larger peak at 60. LEMS not associated with malignancy exhibits a near-normal survival rate, providing a more favorable prognosis.

• #1 Lambert-Eaton Myasthenic Syndrome (LEMS) Markets, 2017-2030 – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20200821005200/en/Lambert-Eaton-Myasthenic-Syndrome-LEMS-Markets-2017-2030—ResearchAndMarkets.com

  The report delivers an in-depth understanding of the LEMS, historical and forecasted epidemiology as well as the LEMS market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan. […] The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of LEMS, Total Diagnosed Prevalent Cases of LEMS, Gender-specific Diagnosed Prevalent Cases of LEMS, Type-specific Diagnosed Prevalent Cases of LEMS, and Diagnosed Prevalent Cases of LEMS by Malignancy scenario of LEMS in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030. […] Total prevalent cases of LEMS in the 7MM was found to be 5,977 in 2017.

• #1 Lambert-Eaton Myasthenic Syndrome (LEMS): Background, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/1170810-overview

  The true incidence of Lambert-Eaton myasthenic syndrome (LEMS) is unknown. It is estimated to affect about 2.8 people per million worldwide. […] According to one estimate, there are approximately 400 cases in the United States at any given time. However, this estimate does not take into account the number of patients with LEMS who do not have small cell lung cancer (SCLC) or any other identifiable malignancy. […] An estimated 3% of patients with SCLC have LEMS. The prevalence of SCLC is 5 cases per million population in the United States. Because only 50-70% of patients with LEMS have an identifiable cancer and because LEMS goes undiagnosed in many patients, the true total prevalence of LEMS may be considerably higher. […] The overwhelming majority of cancers associated with LEMS are SCLC. However, many different malignancies may be involved. A partial list includes non-SCLC; neuroendocrine carcinomas; lymphosarcoma; malignant thymoma; cancers of the breast, stomach, colon, prostate, bladder, kidney, gallbladder, and rectum; basal cell carcinoma; leukemia; lymphoproliferative disorders such as Castleman syndrome; and Hodgkin lymphoma.

• #1 Orphanet: Lambert-Eaton myasthenic syndrome

  https://www.orpha.net/en/disease/detail/43393

  Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune, presynaptic disorder of neuromuscular transmission characterized by fluctuating muscle weakness and autonomic dysfunction frequently associated with small-cell lung cancer (SCLC). […] The prevalence is estimated to be between 1/250,000- 1/333,300 worldwide. […] Tumors, mostly SCLC, are present in fifty to sixty percent of LEMS patients. […] The diagnosis of LEMS almost invariably precedes the discovery of SCLC. […] Life expectancy depends on the presence of lung cancer. Without cancer, the life expectancy is considered normal. As SCLC is a very aggressive cancer, prognosis of patients with LEMS and SCLC is often rather poor. Median survival is 17-24 months, although the amount of patients with long-standing remission or cured is approximately 20%.

• #1 Lambert-Eaton Myasthenic syndrome: early diagnosis is key | DNND

  https://www.dovepress.com/lambert-eaton-myasthenic-syndrome-early-diagnosis-is-key-peer-reviewed-fulltext-article-DNND

  The P-LEMS form is more frequent among men (65%) and occurs at a median age of 60 years. […] The median duration of the disease prior to diagnosis among all LEMS cases was 11 months and was significantly shorter among the patients with P-LEMs than those with A-LEMS (3.5 vs 17 months, respectively). […] A diagnosis of LEMS anticipates tumor detection in most P-LEMS cases. […] Titulaer et al observed that a SCLC diagnosis preceded LEMS identification in only 6% of P-LEMS cases.

• #1 Clinical, Pathophysiological and Electrodiagnostic Aspects of Lambert-Eaton Myasthenic Syndrome | IntechOpen

  https://www.intechopen.com/online-first/87108

  Elrington et al., in a prospective study, demonstrated that LEMS has a higher incidence in males, ranging from 60% to 75% of patients, which differs from MG, where most of the conditions present in women. […] Another factor to be noted is the age of onset, in which the patient with the presence of a non-paraneoplastic form, the age is similar to that of MG, ranging around 35 years. […] In contrast, in paraneoplastic LEMS, the peak incidence generally remains at 58 years of age. […] When we compare the prevalence of MG compared to LEMS, the occurrence of the first disease is 46 times higher. […] The prognosis of the disease is related to the presence of cancer and the severity/distribution of muscle weakness, in which the cause of death in these patients is mainly due to tumor progression. […] LEMS is a clinically important early indicator of possible cancer; therefore, a diagnosis of LEMS should immediately prompt rigorous oncologic screening and surveillance.

• #1 Lambert-Eaton Myasthenic Syndrome (LEMS): Background, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/1170810-overview

  LEMS usually begins in later adulthood and is primarily a disease of middle-aged and older people. The most common age for the appearance of symptoms is 60 years. It is rare in children; however, at least 7 children younger than 17 years are reported to have had LEMS. […] In earlier reports, LEMS occurred in males more frequently than females, by a ratio of almost 2:1. However, current reports note almost equal frequency in men and women.

• #1 Diagnosis and Treatment of Lambert-Eaton Myasthenic Syndrome

  https://practicalneurology.com/articles/2024-apr/diagnosis-and-treatment-of-lambert-eaton-myasthenic-syndrome

  LEMS has an estimated prevalence of 10 per million. However, epidemiologic studies indicate that LEMS is approximately 50 times less common than myasthenia gravis (MG), and another study estimated a prevalence of 2.6 to 3.3 per million individuals. Tumor-associated LEMS more commonly affects men, with 1 LEMS series showing 70% male prevalence, whereas nontumor-associated LEMS affected slightly more women than men. Age at onset varies with LEMS type, with tumor-associated LEMS having a median age at onset of 58 to 60 years and nontumor-associated LEMS having a median age at onset of 50 to 54 years. Nontumor-associated LEMS has 2 peak median ages at onset: a peak at 35 years and another peak that overlaps with the median age at onset of tumor-associated LEMS. […] Individuals with nontumor-associated LEMS have a normal life expectancy but experience chronic symptoms that impair functional abilities and affect quality of life. Individuals with tumor-associated LEMS have a poor long-term survival rate as a result of the associated malignancy. In the context of LEMS associated with SCLC, the median survival is approximately 18 months. Median survival in individuals with SCLC and LEMS is better than those with only SCLC (median survival of 17 vs 7 months). This longer survival was seen in both limited SCLC (median survival of 19 vs 12.1 months) and extensive SCLC (13 vs 4.9 months). Individuals with nontumor-associated LEMS have a similar life expectancy to the general population.

• #1 :: JCN :: Journal of Clinical Neurology

  https://thejcn.com/DOIx.php?id=10.3988/jcn.2024.0018

  Thus, there are three distinct features in pediatric LEMS compared with adult LEMS: low malignancy rate (16%), low rate of dysautonomia, and high rate of antecedent infection (11%). […] Adult LEMS was reported to be associated with SCLC in 50%70% of cases, while, in pediatric LEMS, the malignancy rate was found to be low (16%) and the association was with blood cancer. […] Postinfectious LEMS was not reported in adult LEMS.

• #1 Lambert-Eaton Myasthenic Syndrome Market Report 2034

  https://www.imarcgroup.com/lambert-eaton-myasthenic-syndrome-market

  The 7 major Lambert-Eaton myasthenic syndrome markets are expected to exhibit a CAGR of 5.15% during 2024-2034. […] The Lambert-Eaton myasthenic syndrome market has been comprehensively analyzed in IMARC’s new report titled „Lambert-Eaton Myasthenic Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. […] IMARC Group’s new report provides an exhaustive analysis of the Lambert-Eaton myasthenic syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. […] According to the report the United States has the largest patient pool for Lambert-Eaton myasthenic syndrome and also represents the largest market for its treatment. […] This report also provides a detailed analysis of the current Lambert-Eaton myasthenic syndrome marketed drugs and late-stage pipeline drugs.

• #1 Lambert-Eaton Myasthenic Syndrome (LEMS) Markets, 2017-2030 – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20200821005200/en/Lambert-Eaton-Myasthenic-Syndrome-LEMS-Markets-2017-2030—ResearchAndMarkets.com

  Based on the etiology, LEMS is divided into two types; paraneoplastic and idiopathic. […] As per the assessments, in the 7MM, the majority of cases of LEMS are paraneoplastic form as compared to idiopathic form. […] Among the two forms of LEMS, the paraneoplastic form constitutes more than half of the cases and is mostly associated with intrathoracic neoplasms. […] Among the EU-5 countries, Germany witnessed the highest prevalent population accounting for 6.93% of the total prevalent cases in 7MM, followed by France and the United Kingdom. […] Japan was assessed with 21.32% of the total prevalent population, with 1,274 cases observed in 2017. […] Comprehensive insight has been provided into the LEMS epidemiology and treatment.

• #1 Diagnosis and Treatment of Lambert-Eaton Myasthenic Syndrome

  https://practicalneurology.com/articles/2024-apr/diagnosis-and-treatment-of-lambert-eaton-myasthenic-syndrome

  Additional radiologic testing is mandatory in LEMS based on the strong association with malignancy, particularly SCLC. The DELTA-P (Dutch-English LEMS Tumor Association Prediction) score is helpful in predicting risk for future malignancy development and assists in modulating the frequency of imaging studies and other methods to evaluate for SCLC. Repeat screening for cancer every 3 to 6 months is recommended for at least 2 years after the diagnosis of LEMS.

• #1 Update on Amifampridine as a Drug of Choice in Lambert-Eaton Myasthenic Syndrome – touchNEUROLOGY

  https://touchneurology.com/neuromuscular-diseases/journal-articles/update-on-amifampridine-as-a-drug-of-choice-in-lambert-eaton-myasthenic-syndrome-2/

  Lambert-Eaton myasthenic syndrome (LEMS) is a uncommon, but debilitating, neuromuscular disorder that is estimated to affect 2.32 people per million in Europe with a prevalence of up to 3,000 cases in the US. […] More than half the patients with LEMS, particularly male smokers aged over 50 years, present with an underlying malignancy, usually small cell lung cancer (SCLC). […] Because of the high prevalence of SCLC in LEMS, it is mandatory to perform a careful tumor screening, especially in patients with a history of smoking. SCLC is usually identified within 2 years of the diagnosis of LEMS. […] The diagnosis of LEMS may be confirmed by radioimmunoassay of VGCC antibodies, which are believed to be the main pathogenic factors in LEMS, and P/Q VGCC antibodies are detected in 85 % of patients with clinically and electrophysiologically defined LEMS.

• #1 Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort | Scientific Reports

  https://www.nature.com/articles/s41598-020-67571-9

  To evaluate the Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumour Association Prediction (DELTA-P) score in a prospective cohort of patients with newly diagnosed LEMS to assess the clinical validity of this tool in a real-world setting. […] Approximately 60% of LEMS patients have an associated small-cell lung cancer (SCLC), and it is thought that autoantibodies, directed against VGCCs expressed on the tumour surface, cross-react with VGCCs on the presynaptic terminals causing the neurological dysfunction observed. […] Therefore, prompt and intensive screening for SCLC is mandatory in a patient presenting with LEMS. […] Using this screening protocol, SCLC is detected within 12 months of LEMS diagnosis in over 95% of patients. […] The objective of this current study was to evaluate the DELTA-P score for cancer prediction in a new, prospective cohort of patients with newly diagnosed LEMS to assess the clinical validity of this tool in a real-world setting.

• #1 Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort | Scientific Reports

  https://www.nature.com/articles/s41598-020-67571-9

  We found that the DELTA-P score was a very effective tool in predicting SCLC in this new cohort as well, although the score dichotomised less effectively than in the initial study. […] In practice, from our prospective data, this would mean fewer low-risk patients would benefit from a short, two-stage 6 month cancer screening protocol, but similar numbers of high risk patients would require early, intensive screening. […] Although unconfirmed in LEMS, spontaneous tumour regression has been reported in patients with SCLC and Hu-antibody-associated paraneoplastic sensory neuronopathy, which could account for delayed tumour detection in other paraneoplastic neurological presentations, perhaps due to an anti-tumour immune response. […] We found that the performance of the DELTA-P scoring parameter E, erectile dysfunction (males), was significantly poorer than the other items, such that removal of this from the DELTA-P score to generate a 5-item classification improved the ROC AUC, albeit non-significantly. […] Using clinically validated data from a large prospective cohort, we have confirmed that the use of the DELTA-P scoring system at LEMS diagnosis is a robust measure of the risk of developing SCLC.

• #1

  https://link.springer.com/article/10.1007/s00415-024-12206-6

  Lambert-Eaton myasthenic syndrome (LEMS) is a rare neuromuscular autoimmune disease. Prevalence based on a Dutch and an American cohort study is estimated around 3.3-3.4 per million inhabitants. Specific epidemiologic data for Germany is missing. The most common age of onset ranges from 55-60 years. Epidemiological studies estimate LEMS to be associated to carcinoma in up to 60% of cases. Life expectancy of LEMS patients without neoplasia is comparable to the general population. Most LEMS patients reach maximum disease severity before or within the first year of diagnosis. Few studies have analysed health-related quality of life (HRQoL) and perceived physical and mental health in LEMS patients. HRQoL has been indicated to be reduced in LEMS based on assessments of the Short Form-36 (SF-36) as well as the EQ-5D (European Quality of Life 5 Dimensions) questionnaire. We aim to elucidate the burden of disease in LEMS as well as associated risk factors. In this cross-sectional study with a questionnaire-based survey, we demonstrate that HRQoL is markedly lower in LEMS patients compared to the genP as well as MG. The overall burden is particularly high among women and at high disease severity level.

• #1 The epidemiology, demographics and socio-economic aspects of patients with myasthenia gravis and Lambert-eaton syndrome. | CPRD

  https://www.cprd.com/approved-studies/epidemiology-demographics-and-socio-economic-aspects-patients-myasthenia-gravis

  Myasthenic syndromes are a group of diseases affecting the communication between the nerve and muscle. They result in weakness of a variety of muscles including those that move the eyes, those that control swallowing and breathing and those that move arms and legs. Myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS) are caused by antibodies targeting the neuromuscular junction. […] These conditions are all rare making research challenging. A new UK database for patients with myasthenia under hospital care is being created to use for future research. […] Therefore, CPRD will be used to calculate how many people in the UK have MG and LEMS, and how many new cases there are each year. […] The number of hospital admissions per year will also be described. […] To enable the accurate use of the data from the new database in future research, its coverage must be validated by comparison to reliable data obtained from a separate source. Therefore, up-to-date estimates of the epidemiology and use of healthcare services for MG and LEMS are required. CPRD will be used to estimate the incidence, prevalence and percentage of patients with MG or LEMS who are under hospital care, in addition to the incidence of hospital admissions.

• #1 Top Published Expert Doctors for Lambert-Eaton Myasthenic Syndrome

  https://www.findexpertmd.com/d/Lambert-Eaton_Myasthenic_Syndrome?physician=physician

  251 top medical experts on Lambert-Eaton Myasthenic Syndrome across 31 countries and 27 U.S. states, including 114 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants. […] Clinical Trials: at least 23 including 8 Completed, 3 Recruiting.

• #1 Clinical, Pathophysiological and Electrodiagnostic Aspects of Lambert-Eaton Myasthenic Syndrome | IntechOpen

  https://www.intechopen.com/online-first/87108

  Lambert-Eaton myasthenic syndrome (LEMS) is considered a rare disease, which is difficult to diagnose and somewhat underdiagnosed, with an annual incidence corresponding to one-tenth of cases of MG, the main disease in the group of neuromuscular junction disorders. […] Sanders, in a large North American epidemiological study, estimated that the prevalence was 1 in 100,000 of confirmed and probable cases, respectively, being more frequently presented in males and in the older population. […] When we refer to the approximate duration of disease prior to the diagnosis of the case, we have approximately 11 months and it was significantly lower among patients with paraneoplastic etiology than those with the autoimmune portion. […] In addition, in P-LEMS, the average age of onset was 60 years, with 65-75% of patients being male, as previously mentioned.

• #1 Lambert-Eaton myasthenic syndrome | MedLink Neurology

  https://www.medlink.com/articles/lambert-eaton-myasthenic-syndrome

  The annual incidence of myasthenia gravis was 14 times higher than Lambert-Eaton myasthenic syndrome and the prevalence was 46 times higher than Lambert-Eaton myasthenic syndrome, underscoring the overall rarity of the disorder. […] A study from the United States Veterans Affairs population estimated a point prevalence of 2.6 per million confirmed cases. […] There are reports of Lambert-Eaton myasthenic syndrome in children, although an exact estimate of the frequency remains unknown with and without associated neoplasms such as neuroblastoma. […] Approximately 3% of small cell lung cancer cases are estimated to develop Lambert-Eaton myasthenic syndrome. […] It is possible that rare disorders may go undiagnosed, making an understanding of the true incidence at the population level somewhat difficult.

• #2 Clinical, Pathophysiological and Electrodiagnostic Aspects of Lambert-Eaton Myasthenic Syndrome | IntechOpen

  https://www.intechopen.com/online-first/87108

  Lambert-Eaton myasthenic syndrome (LEMS) is considered a rare disease, which is difficult to diagnose and somewhat underdiagnosed, with an annual incidence corresponding to one-tenth of cases of MG, the main disease in the group of neuromuscular junction disorders. […] Sanders, in a large North American epidemiological study, estimated that the prevalence was 1 in 100,000 of confirmed and probable cases, respectively, being more frequently presented in males and in the older population. […] When we refer to the approximate duration of disease prior to the diagnosis of the case, we have approximately 11 months and it was significantly lower among patients with paraneoplastic etiology than those with the autoimmune portion. […] In addition, in P-LEMS, the average age of onset was 60 years, with 65-75% of patients being male, as previously mentioned.

• #2

  https://link.springer.com/article/10.1007/s00415-024-12206-6

  Lambert-Eaton myasthenic syndrome (LEMS) is a rare neuromuscular autoimmune disease. Prevalence based on a Dutch and an American cohort study is estimated around 3.3-3.4 per million inhabitants. Specific epidemiologic data for Germany is missing. The most common age of onset ranges from 55-60 years. Epidemiological studies estimate LEMS to be associated to carcinoma in up to 60% of cases. Life expectancy of LEMS patients without neoplasia is comparable to the general population. Most LEMS patients reach maximum disease severity before or within the first year of diagnosis. Few studies have analysed health-related quality of life (HRQoL) and perceived physical and mental health in LEMS patients. HRQoL has been indicated to be reduced in LEMS based on assessments of the Short Form-36 (SF-36) as well as the EQ-5D (European Quality of Life 5 Dimensions) questionnaire. We aim to elucidate the burden of disease in LEMS as well as associated risk factors. In this cross-sectional study with a questionnaire-based survey, we demonstrate that HRQoL is markedly lower in LEMS patients compared to the genP as well as MG. The overall burden is particularly high among women and at high disease severity level.

• #2 Clinical, Pathophysiological and Electrodiagnostic Aspects of Lambert-Eaton Myasthenic Syndrome | IntechOpen

  https://www.intechopen.com/online-first/87108

  Elrington et al., in a prospective study, demonstrated that LEMS has a higher incidence in males, ranging from 60% to 75% of patients, which differs from MG, where most of the conditions present in women. […] Another factor to be noted is the age of onset, in which the patient with the presence of a non-paraneoplastic form, the age is similar to that of MG, ranging around 35 years. […] In contrast, in paraneoplastic LEMS, the peak incidence generally remains at 58 years of age. […] When we compare the prevalence of MG compared to LEMS, the occurrence of the first disease is 46 times higher. […] The prognosis of the disease is related to the presence of cancer and the severity/distribution of muscle weakness, in which the cause of death in these patients is mainly due to tumor progression. […] LEMS is a clinically important early indicator of possible cancer; therefore, a diagnosis of LEMS should immediately prompt rigorous oncologic screening and surveillance.

• #2

  https://link.springer.com/article/10.1007/s00415-003-1063-7

  We studied the epidemiology of myasthenia gravis (MG) and the Lambert-Eaton myasthenic syndrome (LEMS), and their association with small cell lung carcinoma (SCLC) and thymoma, in a well defined region of the Netherlands. […] A total of 202 patients with MG (20 with thymoma) and ten patients with LEMS (seven with SCLC) were identified. […] LEMS was 46 times less prevalent (2.32 106) than MG (106.1 106), whereas the annual incidence rate of LEMS was 14 times lower (0.48 106) than of MG (6.48 106), reflecting the poor survival of LEMS patients with SCLC. […] This study confirms the increasing prevalence of MG over the last few decades as reported by others, and underscores the relative rarity of LEMS. […] The frequency of LEMS in our patients with SCLC was lower than reported in previous studies.

• #2 Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine – Chan – Annals of Palliative Medicine

  https://apm.amegroups.org/article/view/10782/html

  Lambert-Eaton myasthenic syndrome (LEMS) is an uncommon autoimmune idiopathic or paraneoplastic syndrome producing antibodies against voltage presynaptic calcium channels. […] Approximately sixty percent in cases LEMS is associated with malignancy, usually a small cell carcinoma (SCC) of lung. […] According to previous studies, many patients with LEMS experience remission in both the clinical symptoms of muscle weakness and the electrophysiologic abnormalities after successful treatment of lung SCC. […] However, some of patients might not respond to conventional therapy and eventually require palliative care (PC) service. […] According to previous literature, LMS patients associated with underlying malignancy usually have poor prognosis and most patients will die within 1 year. […] In this regard, the goal of care is to maximize patients quality of life, symptom control and provide psycho-social care.

• #2 Lambert-Eaton myasthenic syndrome: Treatment and prognosis – UpToDate

  https://www.uptodate.com/contents/lambert-eaton-myasthenic-syndrome-treatment-and-prognosis

  Lambert-Eaton myasthenic syndrome (LEMS) is an uncommon disorder of neuromuscular junction transmission with the primary clinical manifestation of muscle weakness. Knowledge of subtle clinical features and laboratory abnormalities that accompany LEMS permits the early identification of the disorder. Early recognition of LEMS is particularly important because of its strong association with small cell lung cancer (SCLC). […] Population studies have consistently shown that approximately one-half of LEMS cases are associated with a malignancy, which is usually SCLC. In a clinical series that included 50 patients with LEMS, SCLC was present in 21 of 25 patients (84 percent) with cancer. […] From the perspective of patients who have SCLC, the incidence and prevalence of LEMS are estimated to be approximately 3 percent each.

• #2 Diagnosis and Treatment of Lambert-Eaton Myasthenic Syndrome

  https://practicalneurology.com/articles/2024-apr/diagnosis-and-treatment-of-lambert-eaton-myasthenic-syndrome

  LEMS has an estimated prevalence of 10 per million. However, epidemiologic studies indicate that LEMS is approximately 50 times less common than myasthenia gravis (MG), and another study estimated a prevalence of 2.6 to 3.3 per million individuals. Tumor-associated LEMS more commonly affects men, with 1 LEMS series showing 70% male prevalence, whereas nontumor-associated LEMS affected slightly more women than men. Age at onset varies with LEMS type, with tumor-associated LEMS having a median age at onset of 58 to 60 years and nontumor-associated LEMS having a median age at onset of 50 to 54 years. Nontumor-associated LEMS has 2 peak median ages at onset: a peak at 35 years and another peak that overlaps with the median age at onset of tumor-associated LEMS. […] Individuals with nontumor-associated LEMS have a normal life expectancy but experience chronic symptoms that impair functional abilities and affect quality of life. Individuals with tumor-associated LEMS have a poor long-term survival rate as a result of the associated malignancy. In the context of LEMS associated with SCLC, the median survival is approximately 18 months. Median survival in individuals with SCLC and LEMS is better than those with only SCLC (median survival of 17 vs 7 months). This longer survival was seen in both limited SCLC (median survival of 19 vs 12.1 months) and extensive SCLC (13 vs 4.9 months). Individuals with nontumor-associated LEMS have a similar life expectancy to the general population.

• #2 Lambert-Eaton myasthenic syndrome – wikidoc

  https://www.wikidoc.org/index.php/Lambert-Eaton_myasthenic_syndrome

  Epidemiology and Demographics […] PARANEOPLASTTIC (LEMS) […] Age of presentation is found to be around 58 years. […] More common in male than female. ( May be explained by the association with the small cell lung cancer ) […] Lambert Eaton Myasthenic Syndrome(LEMS) is a rare disorder which has a very low prevalence than Myasthenia Gravis(MG). It is about 40 times less prevalent than MG, perhaps the incidence is only 10 times lesser than the MG per year. […] Association with the malignancy and its lower prevalence may explain the poor prognosis of the disorder. […] […] […] NON-PARANEOPLASTIC (LEMS) […] Two peaks of incidence in ages around 35 years and a much larger peak at about 60 years. […] Female more than male like other auto immune diseases. […] good prognosis and survival rate is near normal.

• #2 The Role of Mutations on HLA Genes in Lambert-Eaton Myasthenic Syndrome

  https://www.gavinpublishers.com/article/view/the-role-of-mutations-on-hla-genes-in-lambert-eaton-myasthenic-syndrome

  LEMS is characterized by weakness and fatigue, especially in the muscles of the legs and arms. […] The estimated prevalence of LEMS worldwide is about 2.8 per 1 million people, making it a rare disease. […] Approximately 3% of SCLC patients also develop LEMS, but the clinical signs of LEMS usually precede the diagnosis of SCLC (sometimes by years). […] LEMS is very rare in the pediatric population and so far, only 11 children have been reported in the medical literature. […] In people without LEMS without cancer, there is a genetic link to human leukocyte antigen (HLA) genotypes. […] Screening for SCLC is a very important part of the diagnostic process of LEMS. […] The FDA recently approved a new drug to relieve the symptoms associated with muscle weakness called Firdapse (amifampridine).

• #2 Lambert-Eaton Myasthenic Syndrome (LEMS) Markets, 2017-2030 – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20200821005200/en/Lambert-Eaton-Myasthenic-Syndrome-LEMS-Markets-2017-2030—ResearchAndMarkets.com

  Based on the etiology, LEMS is divided into two types; paraneoplastic and idiopathic. […] As per the assessments, in the 7MM, the majority of cases of LEMS are paraneoplastic form as compared to idiopathic form. […] Among the two forms of LEMS, the paraneoplastic form constitutes more than half of the cases and is mostly associated with intrathoracic neoplasms. […] Among the EU-5 countries, Germany witnessed the highest prevalent population accounting for 6.93% of the total prevalent cases in 7MM, followed by France and the United Kingdom. […] Japan was assessed with 21.32% of the total prevalent population, with 1,274 cases observed in 2017. […] Comprehensive insight has been provided into the LEMS epidemiology and treatment.

• #2 Diagnosis and Treatment of Lambert-Eaton Myasthenic Syndrome

  https://practicalneurology.com/articles/2024-apr/diagnosis-and-treatment-of-lambert-eaton-myasthenic-syndrome

  Additional radiologic testing is mandatory in LEMS based on the strong association with malignancy, particularly SCLC. The DELTA-P (Dutch-English LEMS Tumor Association Prediction) score is helpful in predicting risk for future malignancy development and assists in modulating the frequency of imaging studies and other methods to evaluate for SCLC. Repeat screening for cancer every 3 to 6 months is recommended for at least 2 years after the diagnosis of LEMS.

• #2 Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort | Scientific Reports

  https://www.nature.com/articles/s41598-020-67571-9

  We found that the DELTA-P score was a very effective tool in predicting SCLC in this new cohort as well, although the score dichotomised less effectively than in the initial study. […] In practice, from our prospective data, this would mean fewer low-risk patients would benefit from a short, two-stage 6 month cancer screening protocol, but similar numbers of high risk patients would require early, intensive screening. […] Although unconfirmed in LEMS, spontaneous tumour regression has been reported in patients with SCLC and Hu-antibody-associated paraneoplastic sensory neuronopathy, which could account for delayed tumour detection in other paraneoplastic neurological presentations, perhaps due to an anti-tumour immune response. […] We found that the performance of the DELTA-P scoring parameter E, erectile dysfunction (males), was significantly poorer than the other items, such that removal of this from the DELTA-P score to generate a 5-item classification improved the ROC AUC, albeit non-significantly. […] Using clinically validated data from a large prospective cohort, we have confirmed that the use of the DELTA-P scoring system at LEMS diagnosis is a robust measure of the risk of developing SCLC.

• #2 The epidemiology, demographics and socio-economic aspects of patients with myasthenia gravis and Lambert-eaton syndrome. | CPRD

  https://www.cprd.com/approved-studies/epidemiology-demographics-and-socio-economic-aspects-patients-myasthenia-gravis

  Myasthenic syndromes are a group of diseases affecting the communication between the nerve and muscle. They result in weakness of a variety of muscles including those that move the eyes, those that control swallowing and breathing and those that move arms and legs. Myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS) are caused by antibodies targeting the neuromuscular junction. […] These conditions are all rare making research challenging. A new UK database for patients with myasthenia under hospital care is being created to use for future research. […] Therefore, CPRD will be used to calculate how many people in the UK have MG and LEMS, and how many new cases there are each year. […] The number of hospital admissions per year will also be described. […] To enable the accurate use of the data from the new database in future research, its coverage must be validated by comparison to reliable data obtained from a separate source. Therefore, up-to-date estimates of the epidemiology and use of healthcare services for MG and LEMS are required. CPRD will be used to estimate the incidence, prevalence and percentage of patients with MG or LEMS who are under hospital care, in addition to the incidence of hospital admissions.

• #3 Lambert-Eaton Myasthenic Syndrome (LEMS): Treatment and more

  https://www.verywellhealth.com/lambert-eaton-myasthenic-syndrome-lems-5100988

  Lambert-Eaton myasthenic syndrome (LEMS) is a rare disorder, affecting only about one person in 500,000. […] In around 50% to 60% of people with LEMS, these antibodies form as a part of an individuals immune response to a cancer. […] For this reason, its usually recommended that people diagnosed with LEMS receive a computed tomography (CT) scan of the chest. […] Tumor surveillance is another key part of treatment. Even if your imaging tests didnt show any signs of cancer, its possible that you might have a very small cancer that just didnt show up on the test. […] The frequency of screening is based on the likelihood that you have LEMS from a cancer compared to idiopathic LEMS.

• #3 Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort | Scientific Reports

  https://www.nature.com/articles/s41598-020-67571-9

  We found that the DELTA-P score was a very effective tool in predicting SCLC in this new cohort as well, although the score dichotomised less effectively than in the initial study. […] In practice, from our prospective data, this would mean fewer low-risk patients would benefit from a short, two-stage 6 month cancer screening protocol, but similar numbers of high risk patients would require early, intensive screening. […] Although unconfirmed in LEMS, spontaneous tumour regression has been reported in patients with SCLC and Hu-antibody-associated paraneoplastic sensory neuronopathy, which could account for delayed tumour detection in other paraneoplastic neurological presentations, perhaps due to an anti-tumour immune response. […] We found that the performance of the DELTA-P scoring parameter E, erectile dysfunction (males), was significantly poorer than the other items, such that removal of this from the DELTA-P score to generate a 5-item classification improved the ROC AUC, albeit non-significantly. […] Using clinically validated data from a large prospective cohort, we have confirmed that the use of the DELTA-P scoring system at LEMS diagnosis is a robust measure of the risk of developing SCLC.

Zobacz więcej